← Back to Screener
SI-BONE, Inc. Common Stock (SIBN)
Price$13.67
Favorite Metrics
Price vs S&P 500 (26W)-8.72%
Price vs S&P 500 (4W)6.94%
Market Capitalization$639.96M
All Metrics
Book Value / Share (Quarterly)$4.07
P/TBV (Annual)7.39x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)23.60%
Cash Flow / Share (Quarterly)$-0.21
Price vs S&P 500 (YTD)-29.16%
Gross Margin (TTM)79.57%
Net Profit Margin (TTM)-9.41%
EPS (TTM)$-0.44
10-Day Avg Trading Volume0.84M
EPS Excl Extra (TTM)$-0.44
Revenue Growth (5Y)22.31%
EPS (Annual)$-0.44
ROI (Annual)-8.87%
Gross Margin (Annual)79.57%
Net Profit Margin (5Y Avg)-35.89%
Cash / Share (Quarterly)$3.39
Revenue Growth QoQ (YoY)15.00%
ROA (Last FY)-7.92%
Revenue Growth TTM (YoY)20.19%
EBITD / Share (TTM)$-0.39
ROE (5Y Avg)-31.84%
Operating Margin (TTM)-11.11%
Cash Flow / Share (Annual)$-0.21
P/B Ratio3.60x
P/B Ratio (Quarterly)4.82x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.15x
Net Interest Coverage (TTM)-75.63x
ROA (TTM)-8.12%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)8.55x
Quick Ratio (Quarterly)7.03x
3-Month Avg Trading Volume0.59M
52-Week Price Return8.46%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$4.30
P/S Ratio (Annual)3.19x
Asset Turnover (Annual)0.84x
52-Week High$21.89
Operating Margin (5Y Avg)-36.39%
EPS Excl Extra (Annual)$-0.44
CapEx CAGR (5Y)26.87%
26-Week Price Return-4.73%
Quick Ratio (Annual)7.03x
13-Week Price Return-18.91%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)8.55x
Enterprise Value$633.284
Revenue / Share Growth (5Y)13.14%
Asset Turnover (TTM)0.86x
Book Value / Share Growth (5Y)-4.77%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.35x
Pretax Margin (Annual)-9.41%
Cash / Share (Annual)$3.39
3-Month Return Std Dev46.44%
Gross Margin (5Y Avg)82.20%
Net Income / Employee (TTM)$-0
ROE (Last FY)-10.65%
Net Interest Coverage (Annual)-32.63x
EPS Basic Excl Extra (Annual)$-0.44
Receivables Turnover (TTM)7.00x
Total Debt / Equity (Quarterly)0.20x
EPS Incl Extra (TTM)$-0.44
Receivables Turnover (Annual)7.00x
ROI (TTM)-9.12%
P/S Ratio (TTM)3.19x
Pretax Margin (5Y Avg)-35.89%
Revenue / Share (Annual)$4.68
Tangible BV / Share (Annual)$2.83
Price vs S&P 500 (52W)-21.37%
Year-to-Date Return-26.52%
5-Day Price Return5.84%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-21.75%
Net Profit Margin (Annual)-9.41%
Month-to-Date Return14.73%
Cash Flow / Share (TTM)$-1.05
EBITD / Share (Annual)$-0.39
Operating Margin (Annual)-11.11%
LT Debt / Equity (Annual)0.20x
ROI (5Y Avg)-24.91%
LT Debt / Equity (Quarterly)0.20x
EPS Basic Excl Extra (TTM)$-0.44
P/TBV (Quarterly)4.18x
P/B Ratio (Annual)4.82x
Inventory Turnover (TTM)1.35x
Pretax Margin (TTM)-9.41%
Book Value / Share (Annual)$4.07
Price vs S&P 500 (13W)-19.60%
Beta0.80x
Revenue / Share (TTM)$4.62
ROE (TTM)-11.00%
52-Week Low$12.15
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.19
4.19
4.20
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
SIBNSI-BONE, Inc. Common Stock | 3.19x | 22.31% | 79.57% | -11.11% | $13.67 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
SI-BONE Inc. develops and markets minimally invasive surgical implants focused on spine and orthopedic conditions, including its flagship iFuse system for sacroiliac joint fusion. The company's proprietary titanium implants and surgical instruments address high-prevalence conditions such as spinal deformity, degeneration, and pelvic trauma. With operations in the U.S. and internationally, SI-BONE serves the growing orthopedic surgery market through its specialized implant portfolio.